The assessment comes ahead of the FDA's independent expert panel meeting on Tuesday, which will make recommendations on whether or not to clear the use of the device, TriClip, in patients with tricuspid regurgitation (TR). TR is a disorder in which the tricuspid valve that separates the right lower heart chamber from the right upper heart chamber does not close tight enough, potentially causing heart failure.